BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
Announcement of FDA Filing: Biofronterra has announced the acceptance of its supplemental new drug application by the FDA.
Drug Focus: The application is specifically for Ameluz® PDT, which is intended for the treatment of superficial basal cell carcinoma.
Trade with 70% Backtested Accuracy
Analyst Views on BFRIW
No data
About the author
BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026
- Announcement of Date: The BioFrontier AI has set a date for the upcoming event on September 28, 2026.
- Event Significance: This date marks a significant milestone for the organization and its initiatives in the field of artificial intelligence.
BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
Announcement of FDA Filing: Biofronterra has announced the acceptance of its supplemental new drug application by the FDA.
Drug Focus: The application is specifically for Ameluz® PDT, which is intended for the treatment of superficial basal cell carcinoma.
BIOFRONTERA INC PLANS TO FILE SNDA WITH FDA IN Q3 2026
Company Overview: BioFrontier is a company focused on advancing artificial intelligence technologies in various sectors.
Recent Developments: The company has submitted its latest data and findings for Q3 2026, indicating progress in its research and development efforts.
BIOFRONTERA INC Reports 73.1% Lesion Clearance in FAS and 80.3% in PPS
Biofrontier AI: The article discusses advancements in AI technology, particularly in the field of bioinformatics.
Kleisen Clearance: It highlights the effectiveness of the Kleisen clearance method, showing a 73.1% improvement in certain applications.
Infas and PPS: The report mentions significant performance metrics, with Infas achieving a 73.1% clearance rate and PPS reaching 80.3%.
Overall Impact: The advancements in these technologies are expected to have a substantial impact on the healthcare and bioinformatics sectors.
BIOFRONTERA INC - AMELUZ PDT SHOWS 45.6% CLEARANCE RATE IN PHASE 3 TRIAL
- Study Overview: A Phase 3 study has reported a clearance rate of 45.6% for the treatment being evaluated.
- Significance of Results: The findings indicate a potential effectiveness of the treatment in the studied population.
BIOFRONTERA INC - PRIMARY ENDPOINT MET WITH FULL CLEARANCE RATE OF AK LESIONS
Primary Achievement: The BioFrontier AI has successfully achieved a primary endpoint.
Clearance Rate: The project boasts a complete clearance rate of Aklesiions.
BIOFRONTERA INC - FDA Establishes PDUFA Deadline for September 28, 2026
- Announcement of Date: The BioFrontier AI has set a date for the upcoming event on September 28, 2026.
- Event Significance: This date marks a significant milestone for the organization and its initiatives in the field of artificial intelligence.
BIOFRONTERA CONFIRMS FDA ACCEPTANCE OF SUPPLEMENTAL NEW DRUG APPLICATION FOR AMELUZ® PDT IN TREATING SUPERFICIAL BASAL CELL CARCINOMA
Announcement of FDA Filing: Biofronterra has announced the acceptance of its supplemental new drug application by the FDA.
Drug Focus: The application is specifically for Ameluz® PDT, which is intended for the treatment of superficial basal cell carcinoma.
BIOFRONTERA INC PLANS TO FILE SNDA WITH FDA IN Q3 2026
Company Overview: BioFrontier is a company focused on advancing artificial intelligence technologies in various sectors.
Recent Developments: The company has submitted its latest data and findings for Q3 2026, indicating progress in its research and development efforts.
BIOFRONTERA INC Reports 73.1% Lesion Clearance in FAS and 80.3% in PPS
Biofrontier AI: The article discusses advancements in AI technology, particularly in the field of bioinformatics.
Kleisen Clearance: It highlights the effectiveness of the Kleisen clearance method, showing a 73.1% improvement in certain applications.
Infas and PPS: The report mentions significant performance metrics, with Infas achieving a 73.1% clearance rate and PPS reaching 80.3%.
Overall Impact: The advancements in these technologies are expected to have a substantial impact on the healthcare and bioinformatics sectors.
BIOFRONTERA INC - AMELUZ PDT SHOWS 45.6% CLEARANCE RATE IN PHASE 3 TRIAL
- Study Overview: A Phase 3 study has reported a clearance rate of 45.6% for the treatment being evaluated.
- Significance of Results: The findings indicate a potential effectiveness of the treatment in the studied population.
BIOFRONTERA INC - PRIMARY ENDPOINT MET WITH FULL CLEARANCE RATE OF AK LESIONS
Primary Achievement: The BioFrontier AI has successfully achieved a primary endpoint.
Clearance Rate: The project boasts a complete clearance rate of Aklesiions.
